Alexion: ALXN1210 Shows Rapid, Sustained Reductions In LDH - Quick Facts

(RTTNews) - Alexion Pharmaceuticals, Inc. (ALXN) announced that interim results from the Phase 1/2 study of ALXN1210 in patients with paroxysmal nocturnal hemoglobinuria, showed rapid, complete, and sustained complement inhibition, as measured by reductions in LDH, or lactate dehydrogenase, levels, with a once-monthly dosing regimen in all treated patients. No serious adverse events or study withdrawals were observed in either patient cohort. The company said a Phase 2 study is ongoing to evaluate the safety and efficacy of ALXN1210 in additional dosing cohorts evaluating longer dosing intervals.

The company also reported additional interim results from an ongoing Phase 2, open-label study of ALXN1007 in patients with newly diagnosed acute graft-versus-host disease of the lower GI tract. The study showed an overall 28-day response rate of 77 percent in ALXN1007-treated patients.